NASDAQ:GNFT GENFIT S A/ADR Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GENFIT S A/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.19 +0.52 (+14.17 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$3.93Now: $4.19▼$4.5850-Day Range$3.67MA: $4.84▼$5.2152-Week Range$3.65Now: $4.19▼$22.48Volume209,907 shsAverage Volume72,985 shsMarket Capitalization$158.52 millionP/E RatioN/ADividend YieldN/ABeta0.68 ProfileAnalyst RatingsChartCompetitorsInstitutional OwnershipHeadlinesShort InterestSocial Media Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingGENFIT S A/ADR has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 4 buy ratings, 3 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.60, GENFIT S A/ADR has a forecasted upside of 964.4% from its current price of $4.19.Amount of Analyst CoverageGENFIT S A/ADR has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesGENFIT S A/ADR has received 45 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGENFIT S A/ADR has received 40 “underperform” votes. (Add your “underperform” vote.)Community SentimentGENFIT S A/ADR has received 52.94% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GENFIT S A/ADR and other stocks. Vote “Outperform” if you believe GNFT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNFT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGENFIT S A/ADR does not currently pay a dividend.Dividend GrowthGENFIT S A/ADR does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GENFIT S A/ADR insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.04% of the stock of GENFIT S A/ADR is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GENFIT S A/ADR are expected to grow in the coming year, from ($2.31) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GENFIT S A/ADR is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GENFIT S A/ADR is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGENFIT S A/ADR has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.26 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNFT Previous Symbol CUSIPN/A CIKN/A Webwww.genfit.com Phone33-3-20-16-40-00Debt Debt-to-Equity Ratio2.13 Current Ratio6.66 Quick Ratio6.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$45.88 million Price / Sales3.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.49 per share Price / Book1.68Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees148 Outstanding Shares37,833,000Market Cap$158.52 million Next Earnings DateN/A OptionableNot Optionable $4.19 +0.52 (+14.17 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GNFT News and Ratings via Email Sign-up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. GENFIT S A/ADR (NASDAQ:GNFT) Frequently Asked Questions How has GENFIT S A/ADR's stock been impacted by Coronavirus (COVID-19)? GENFIT S A/ADR's stock was trading at $14.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GNFT stock has decreased by 70.6% and is now trading at $4.19. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of GENFIT S A/ADR? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 3 sell ratings, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GENFIT S A/ADR. What price target have analysts set for GNFT? 10 Wall Street analysts have issued 1 year price objectives for GENFIT S A/ADR's shares. Their forecasts range from $7.00 to $174.00. On average, they expect GENFIT S A/ADR's stock price to reach $44.60 in the next twelve months. This suggests a possible upside of 964.4% from the stock's current price. View analysts' price targets for GENFIT S A/ADR. Are investors shorting GENFIT S A/ADR? GENFIT S A/ADR saw a increase in short interest in September. As of September 15th, there was short interest totaling 13,800 shares, an increase of 42.3% from the August 31st total of 9,700 shares. Based on an average daily trading volume, of 32,600 shares, the short-interest ratio is currently 0.4 days. View GENFIT S A/ADR's Short Interest. Who are some of GENFIT S A/ADR's key competitors? Some companies that are related to GENFIT S A/ADR include Tcr2 Therapeutics (TCRR), Passage Bio (PASG), Poseida Therapeutics (PSTX), Allovir (ALVR), Autolus Therapeutics (AUTL), Scholar Rock (SRRK), Aerie Pharmaceuticals (AERI), Aptose Biosciences (APTO), Fusion Pharmaceuticals (FUSN), Avrobio (AVRO), Oyster Point Pharma (OYST), CEL-SCI (CVM), Brainstorm Cell Therapeutics (BCLI), MeiraGTx (MGTX) and BIONDVAX PHARMA/S (BVXV). View all competitors. What other stocks do shareholders of GENFIT S A/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other GENFIT S A/ADR investors own include Intercept Pharmaceuticals (ICPT), InterDigital Wireless (IDCC), Stag Industrial (STAG), Amarin (AMRN), Gilead Sciences (GILD), Occidental Petroleum (OXY), Vaxart (VXRT), Exxon Mobil (XOM), Zynerba Pharmaceuticals (ZYNE) and Aimmune Therapeutics (AIMT). Who are GENFIT S A/ADR's key executives? GENFIT S A/ADR's management team includes the following people: Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)Dr. Dean W. Hum, Chief Operating Officer (Age 57)Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49) When did GENFIT S A/ADR IPO? (GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers. What is GENFIT S A/ADR's stock symbol? GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT." Who are GENFIT S A/ADR's major shareholders? GENFIT S A/ADR's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ikarian Capital LLC (0.17%). Which institutional investors are buying GENFIT S A/ADR stock? GNFT stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC. How do I buy shares of GENFIT S A/ADR? Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GENFIT S A/ADR's stock price today? One share of GNFT stock can currently be purchased for approximately $4.19. How big of a company is GENFIT S A/ADR? GENFIT S A/ADR has a market capitalization of $158.52 million and generates $45.88 million in revenue each year. The company earns $-72,960,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. GENFIT S A/ADR employs 148 workers across the globe. What is GENFIT S A/ADR's official website? The official website for GENFIT S A/ADR is www.genfit.com. How can I contact GENFIT S A/ADR? GENFIT S A/ADR's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected] This page was last updated on 9/27/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
